Business
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary data of two clinical trials, HER3 ADC candidate DB-1310 and B7H3 ADC candidate DB-1311/BNT324, which is being jointly developed with BioNTech, in Oral/Rapid Oral presentations.
About this update from Duality Biotherapeutics, Inc.
[{"type":"text","content":"SHANGHAI and CHICAGO, June 4, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary data of two clinical trials, HER3 ADC candidate DB-1310 and B7H3 ADC candidate DB-1311/BNT324, which is being jointly developed with BioNTech, in Oral/Rapid Oral presentations.","length":370,"tagName":"p"},{"type":"text","content":"B7H3 ADC candidate DB-1311/BNT324:","length":34,"tagName":"p"},{"type":"text","content":"Data from the ongoing Phase 1/2 clinical trial (NCT05914116) in patients with heavily pre-treated castration-resistant prostate cancer (CRPC) were presented during an oral session on BNT324/DB-1311, an B7H3-targeted ADC candidate.","length":235,"tagName":"p"},{"type":"image","alt":"Dr. Andrew Parsonson delivering the rapid oral presentation at the ASCO 2025 meeting in Chicago, USA.","displaySize":"","headline":null,"caption":"Dr. Andrew Parsonson delivering the rapid oral presentation at the ASCO 2025 meeting in Chicago, USA.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":300,"url":"https://media.zenfs.com/en/prnewswire.com/c5f509ebd2edab8d84ae94c1fd6a0006"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EadFjv7ukqAAtt4.6EfQ9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c5f509ebd2edab8d84ae94c1fd6a0006","width":400,"height":300}},"href":"https://mma.prnewswire.com/media/2703868/Dr_Andrew_Parsonson_delivering_rapid_oral_presentation_ASCO_2025_meeting.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The data indicated early clinical activity and a manageable safety profile with low discontinuation rates. Most common adverse events were gastrointestinal and hematologic toxicities. In the 52 efficacy evaluable patients with heavily pretreated CRPC based on RCIST v1.1, the confirmed objective response rate (cORR) was 30.8%, DCR was 90.4%. Among 68 evaluable patients, the 6-month rPFS rate was 69.8%. Similar outcomes were observed across both dose levels (6 mg/kg or 9 mg/kg). Outcomes appeared better in earlier treatment lines and in patients who received one prior NHT, while antitumor activity was also observed in later lines and regardless of type of prior treatment or metastatic site.","length":697,"tagName":"p...